A Phase I/II, Multi-Center, Open Label Study of Vorinostat Plus Melphalan and Prednisone (ZMP) in Advanced, Refractory Multiple Myeloma Patients.

Trial Profile

A Phase I/II, Multi-Center, Open Label Study of Vorinostat Plus Melphalan and Prednisone (ZMP) in Advanced, Refractory Multiple Myeloma Patients.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 05 May 2017

At a glance

  • Drugs Melphalan (Primary) ; Prednisone (Primary) ; Vorinostat (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 02 May 2017 Planned End Date changed from 1 Mar 2017 to 1 May 2017.
    • 09 May 2016 Planned End Date changed from 1 Mar 2014 to 1 Mar 2017.
    • 10 Dec 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top